[Abstract]: Objective To investigate the efficacy of the combination therapy of bromovudine and recombinant human interferon a-2b in the treatment of herpes zoster patients. Method: 96 patients with herpes zoster admitted to our hospital from March 2021 to January 2024 were randomly divided into a monotherapy group (n=48) and a combination group (n=48) using a random number table. The monotherapy group was treated with bromovudine, while the combination group was treated with recombinant human interferon a-2b for 7 consecutive days. Compare the efficacy, symptom improvement time, pain level, inflammatory response, peripheral blood T cell subsets, adverse reactions, and residual neuropathic pain between two groups. The total effective rate of the combined treatment group (95.83%) was higher than that of the monotherapy group (81.25%), with statistical differences (P<0.05); The improvement time of each symptom in the combination group was shorter than that in the monotherapy group, with statistical differences (P<0.05); After treatment, the visual analogue scale (Visual analogue scale，VAS) scores, （interleukin）IL -18 , IL-6, and tumor necrosis factor - α (Tumor Necrosis Factor-α，TNF - α) levels in both groups were lower than before treatment, while the combination group was lower than the monotherapy group, with statistical differences (P<0.05); After treatment, the CD8+detection values of both groups were lower than before treatment, and CD4+and CD4+/CD8+were higher than before treatment. However, the CD8+detection values of the combination group were lower than those of the monotherapy group, and CD4+and CD4+/CD8+were higher than those of the monotherapy group, with statistical differences (P<0.05); During the treatment process, neither group experienced significant adverse reactions; The incidence of postoperative neuropathic pain in the combination group was 4.17% (2/48), which was lower than the 16.67% (8/48) in the monotherapy group, with statistical significance (P<0.05). Conclusion: The combination of recombinant human interferon a-2b and bromovudine in the treatment of herpes zoster is safe, can enhance efficacy, shorten symptom relief time, improve inflammatory response and immune function, alleviate patient neuropathic pain, and reduce the incidence of postoperative neuropathic pain.